Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
Agilent Technologies (NYSE: A) has announced its contribution to the FDA approval of AUCATZYL®, a CAR T therapy developed by Autolus Therapeutics. The company's xCELLigence Real-Time Cell Analysis (RTCA) technology played a important role in developing and validating the therapy's potency assay.
The xCELLigence RTCA platform provides continuous, real-time monitoring of cell behavior without labels or dyes, using electrical impedance to measure cell numbers, viability, and morphology. This technology offers advantages over traditional endpoint assays by enabling more accurate and timely decision-making in drug development.
Agilent and Autolus will present their findings at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, discussing lessons learned in CAR T Cell Product Potency Measurement.
Agilent Technologies (NYSE: A) ha annunciato il suo contributo all'approvazione da parte della FDA di AUCATZYL®, una terapia CAR T sviluppata da Autolus Therapeutics. La tecnologia xCELLigence Real-Time Cell Analysis (RTCA) dell'azienda ha svolto un ruolo importante nello sviluppo e nella validazione dell'assay di potenza della terapia.
La piattaforma xCELLigence RTCA fornisce un monitoraggio continuo e in tempo reale del comportamento cellulare senza l'uso di marcatori o coloranti, utilizzando l'impedenza elettrica per misurare il numero di cellule, la vitalità e la morfologia. Questa tecnologia offre vantaggi rispetto ai tradizionali assay endpoint consentendo decisioni più accurate e tempestive nello sviluppo di farmaci.
Agilent e Autolus presenteranno i loro risultati alla 2025 Hybrid US Bioassay Conference a Tucson, Arizona, discutendo le lezioni apprese nella misurazione della potenza del prodotto CAR T Cell.
Agilent Technologies (NYSE: A) ha anunciado su contribución a la aprobación de la FDA de AUCATZYL®, una terapia CAR T desarrollada por Autolus Therapeutics. La tecnología xCELLigence Real-Time Cell Analysis (RTCA) de la compañía jugó un papel importante en el desarrollo y la validación del ensayo de potencia de la terapia.
La plataforma xCELLigence RTCA proporciona un monitoreo continuo y en tiempo real del comportamiento celular sin etiquetas ni colorantes, utilizando la impedancia eléctrica para medir el número de células, la viabilidad y la morfología. Esta tecnología ofrece ventajas sobre los ensayos tradicionales de punto final al permitir una toma de decisiones más precisa y oportuna en el desarrollo de fármacos.
Agilent y Autolus presentarán sus hallazgos en la Conferencia Híbrida de Bioensayos de EE. UU. 2025 en Tucson, Arizona, discutiendo las lecciones aprendidas en la medición de la potencia del producto CAR T Cell.
Agilent Technologies (NYSE: A)는 Autolus Therapeutics가 개발한 CAR T 치료제 AUCATZYL®의 FDA 승인을 위한 기여를 발표했습니다. 회사의 xCELLigence Real-Time Cell Analysis (RTCA) 기술은 치료의 효능 분석 개발 및 검증에서 중요한 역할을 했습니다.
xCELLigence RTCA 플랫폼은 전기 임피던스를 사용하여 세포 수, 생존율 및 형태를 측정하면서 라벨이나 염료 없이 세포 행동을 지속적으로 실시간으로 모니터링합니다. 이 기술은 약물 개발에서 보다 정확하고 시기 적절한 의사 결정을 가능하게 하여 전통적인 종단적 분석에 비해 장점을 제공합니다.
Agilent와 Autolus는 2025 Hybrid US Bioassay Conference에서 애리조나주 투손에서 CAR T 세포 제품의 효능 측정에서 얻은 교훈에 대해 논의할 것입니다.
Agilent Technologies (NYSE: A) a annoncé sa contribution à l'approbation par la FDA de AUCATZYL®, une thérapie CAR T développée par Autolus Therapeutics. La technologie xCELLigence Real-Time Cell Analysis (RTCA) de l'entreprise a joué un rôle important dans le développement et la validation de l'essai de puissance de la thérapie.
La plateforme xCELLigence RTCA offre une surveillance continue et en temps réel du comportement cellulaire sans étiquettes ni colorants, utilisant l'impédance électrique pour mesurer le nombre de cellules, la viabilité et la morphologie. Cette technologie présente des avantages par rapport aux essais de point final traditionnels en permettant une prise de décision plus précise et opportune dans le développement de médicaments.
Agilent et Autolus présenteront leurs résultats lors de la conférence hybride sur les bioessais des États-Unis de 2025 à Tucson, en Arizona, discutant des leçons tirées de la mesure de la puissance des produits CAR T Cell.
Agilent Technologies (NYSE: A) hat seinen Beitrag zur FDA-Zulassung von AUCATZYL®, einer von Autolus Therapeutics entwickelten CAR T-Therapie, bekannt gegeben. Die Technologie xCELLigence Real-Time Cell Analysis (RTCA) des Unternehmens spielte eine wichtige Rolle bei der Entwicklung und Validierung des Potenzassays der Therapie.
Die xCELLigence RTCA-Plattform bietet eine kontinuierliche, Echtzeitüberwachung des Zellverhaltens ohne Marker oder Farbstoffe, indem elektrische Impedanz verwendet wird, um Zellzahlen, Lebensfähigkeit und Morphologie zu messen. Diese Technologie bietet Vorteile gegenüber herkömmlichen Endpunktassays, da sie genauere und zeitgerechtere Entscheidungen in der Arzneimittelentwicklung ermöglicht.
Agilent und Autolus werden ihre Ergebnisse auf der 2025 Hybrid US Bioassay Conference in Tucson, Arizona, präsentieren und die gewonnenen Erkenntnisse zur Messung der Potenz von CAR T-Zell-Produkten diskutieren.
- Technology validation through FDA approval of AUCATZYL demonstrates market leadership in cell analysis
- Strategic partnership with Autolus Therapeutics strengthens position in CAR T therapy development
- xCELLigence RTCA technology offers competitive advantages over traditional endpoint assays
- None.
Insights
Agilent's xCELLigence Real-Time Cell Analysis (RTCA) technology has achieved a significant industry validation by supporting the FDA approval process for Autolus Therapeutics' AUCATZYL®, a CAR T cell therapy. This demonstrates the technology's capability to perform critical potency assays - essential tests that verify a cell therapy's functionality and consistency.
The xCELLigence system's ability to continuously monitor cell behavior without labels provides distinct advantages over traditional endpoint assays. For cell therapy developers, this translates to more accurate characterization of cellular responses and potentially streamlined regulatory submissions. Having technology that's proven effective in an FDA approval process positions Agilent favorably among companies developing advanced cellular therapies.
While the article doesn't quantify the financial relationship between Agilent and Autolus, this validation serves as a practical case study that Agilent can leverage in marketing efforts. The public endorsement from Autolus' CTO calling Agilent's support "invaluable" further strengthens this positioning.
This announcement primarily highlights Agilent's technical capabilities in supporting complex biological product development rather than revealing new revenue streams or material business developments. However, it reinforces Agilent's strategic position in the cell analysis instrumentation market, particularly for advanced therapy medicinal products requiring sophisticated analytical tools.
Innovative technology supports testing of accuracy and reliability in Autolus Therapeutics’ recently approved CAR T therapy AUCATZYL®
Dr. Xiaobo Wang, Vice President and General Manager of the Cell Function and Phenotyping Business at Agilent stated, "Agilent is honored to have contributed to this significant milestone in cancer treatment. The collaboration between Agilent and Autolus highlights the importance of innovative technologies and cooperative efforts in advancing cancer therapies."
David Brochu, Chief Technical Officer at Autolus Therapeutics added, "Agilent's support was invaluable in our journey to FDA approval. Agilent’s state-of-the-art xCELLigence RTCA technology facilitated the accuracy, reliability and precision of our potency analytical procedure."
The xCELLigence Real-Time Cell Analysis (RTCA) technology is a cutting-edge platform that continuously monitors cell behavior in real-time without using labels or dyes. This technology measures electrical impedance to provide dynamic information on cell numbers, viability, and morphology. Unlike traditional endpoint assays, xCELLigence RTCA offers real-time insights, enabling more accurate and timely decision-making in drug development. Its ability to deliver continuous, real-time data sets it apart in the market, providing researchers with a deeper understanding of cellular responses and enhancing the development of effective therapies.
Agilent and Autolus will attend the 2025 Hybrid US Bioassay Conference from March 24-25 in
Agilent is committed to advancing scientific innovation and supporting groundbreaking therapies that enhance health outcomes. To learn more about Agilent’s real-time cell analysis solutions, visit Agilent Cell Analysis.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324197742/en/
Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com
Source: Agilent Technologies Inc.
FAQ
How did Agilent's xCELLigence RTCA technology contribute to AUCATZYL's FDA approval?
What are the key features of Agilent's xCELLigence RTCA technology?
When will Agilent (NYSE: A) present their findings on AUCATZYL at the US Bioassay Conference?
What advantages does Agilent's xCELLigence RTCA offer over traditional cell analysis methods?
